Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Portola Pharmaceuticals Inc    PTLA

PORTOLA PHARMACEUTICALS INC (PTLA)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/08/2018 10/09/2018 10/10/2018 10/11/2018 10/12/2018 Date
24.16(c) 24.19(c) 23.85(c) 23.31(c) 24.05(c) Last
809 055 1 033 525 1 387 152 1 416 970 1 046 921 Volume
-0.17% +0.12% -1.41% -2.26% +3.17% Change
More quotes
Financials (USD)
Sales 2018 29,8 M
EBIT 2018 -386 M
Net income 2018 -391 M
Finance 2018 457 M
Yield 2018 -
Sales 2019 144 M
EBIT 2019 -262 M
Net income 2019 -247 M
Debt 2019 5,88 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 38,0x
EV / Sales2019 11,1x
Capitalization 1 589 M
More Financials
Company
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis and hematologic disorders, and inflammation.Its FDA-approved medicines include Bevyxxa (betrixaban), the oral, once-daily Factor Xa inhibitor, and Andexxa coagulation... 
More about the company
Surperformance© ratings of Portola Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PORTOLA PHARMACEUTICALS IN
10/12PORTOLA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
AQ
10/10PORTOLA PHARMACEUTICALS : Supports 2018 World Thrombosis Day Campaign to Raise A..
AQ
10/09Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise ..
GL
09/28PORTOLA PHARMACEUTICALS : Receives FDA Orphan Drug Designation for Cerdulatinib,..
AQ
09/25Portola Pharmaceuticals Receives FDA Orphan Drug Designation for Cerdulatinib..
GL
09/20PORTOLA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
AQ
09/20Portola Pharmaceuticals Names Scott Garland President and Chief Executive Off..
GL
09/13PORTOLA PHARMACEUTICALS : U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals..
AQ
09/12PORTOLA PHARMACEUTICALS : U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals..
AQ
09/12U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval ..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/13Morgan Stanley Cuts Portola Pharmaceuticals $PTLA Price Target to $32.00  
10/12Portola Pharmaceuticals $PTLA PT Lowered to $32.00 at Morgan Stanley  
10/11Portola Pharmaceuticals $PTLA Upgraded to Buy by Zacks Investment Research  
10/11Get the latest news and updates for $PTLA $RACE $XGTI $CMFN $ZS automatically.. 
10/10Portola Pharmaceuticals $PTLA Hits New 52-Week Low at $23.54  
More tweets
Qtime:66
News from SeekingAlpha
09/25Portola Pharma's cerdulatinib an Orphan Drug in U.S. for type of lymphoma 
09/20Portola Pharmaceuticals names Scott Garland President and CEO 
09/07Portola Pharmaceuticals' chief commercial officer bids adieu 
09/03YOUR DAILY SCOOP : Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial.. 
08/31Portola Pharma files U.S. application for Gen 2 Andexxa manufacturing process.. 
Chart PORTOLA PHARMACEUTICALS INC
Duration : Period :
Portola Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PORTOLA PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 44,8 $
Spread / Average Target 86%
EPS Revisions
Managers
NameTitle
J. Scott Garland President, Chief Executive Officer & Director
Hollings Chase Renton Chairman
Mardi C. Dier Chief Financial Officer & Executive Vice President
John T. Curnutte EVP-Research & Development
W. Richey Neuman Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
PORTOLA PHARMACEUTICALS INC-50.60%1 540
CELLTRION, INC.--.--%30 463
IQVIA HOLDINGS INC27.47%24 833
LONZA GROUP18.72%23 465
INCYTE CORPORATION-33.95%13 127
SEATTLE GENETICS, INC.36.02%11 255